CTIS2024-513861-38-00Active, not recruitingPhase 1
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications - EDP 938-104
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enanta Pharmaceuticals Inc.
- Enrollment
- 111
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 65+ (—)
- Sex
- All
Inclusion Criteria
- •1. The subject has signed and dated the ICFs., 10. Female subject must agree to refrain from egg donation from the date of Screening until 30 days after their last dose of study drug., 11. Subject is willing and able to adhere to the assessments, visit schedule, prohibitions, and restrictions, as described in this protocol., 2. The subject is a male or female adult at least 18 years of age, who has at least one of the following conditions that predispose them to complications after RSV infection: a. Age =65 years; b. CHF (NYHA Class I to IV)[New York Heart Association Criteria Committee, 1994]; c. Asthma; d. COPD . Note: Subjects with COPD and a diagnosis of alpha-1-anti-trypsin deficiency must have a transient elastography indicating no evidence of significant liver fibrosis (i.e., >7 kPa) or cirrhosis (i.e., >11 kPa)., 3. The subject has a new onset of any of the following symptom(s) or worsening of preexisting symptom(s) consistent with a respiratory tract infection no more than 72 hours prior to the administration of the first dose of study drug: feeling feverish, headache, neck pain, fatigue, loss of appetite, interrupted sleep, body aches, sore throat, nasal congestion, cough, cough with phlegm, wheezing, or short of breath. Note: The duration of new onset of symptom(s) or worsening of pre-existing symptom(s) is to be measured from the estimated time of onset of the first symptom to the anticipated time of dosing with the study drug, 4. The subject reports at least 2 of the following symptoms, one of which must be reported as at least 'moderate' severity by the subject using the RiiQ™: cough, cough with phlegm, wheezing, or short of breath., 5. The subject has tested positive for RSV infection using a NAAT (polymerase chain reaction [PCR] or other) on a nasal swab sample., 6. The subject has a body mass index =18 kg/m2 and =40 kg/m2, 7. A heterosexually active female subject must agree to use 2 effective birth control methods for the duration of the study and for 30 days after the last dose of study drug, or be surgically sterile for at least 6 months or postmenopausal; subjects who are <2 years postmenopausal will require a confirmatory serum follicle stimulating hormone (FSH) level >35 IU/mL. Note: Effective birth control methods include male or female condom (may not be used together), intrauterine device (IUD), or systemic hormonal (i.e., oral, injectable, implantable, transdermal, or intravaginal) contraception associated with the inhibition of ovulation started a minimum of 2 weeks prior to signing the Study ICF: a. A heterosexually active female subject with a single male partner who has been vasectomized is not required to use another effective birth control method. b. A female subject who practices sexual abstinence is not required to use another effective birth control method., 8. A heterosexually active male subject and their female partner(s) of childbearing potential must agree to use 2 effective birth control methods for the duration of the study and for 90 days after the last dose of study drug. Note: Effective birth control methods include male or female condom (may not be used together), systemic hormonal contraception associated with the inhibition of ovulation started a minimum of 2 weeks prior to signing the Study ICF, or IUD. a. A vasectomized heterosexually active male subject with a single female partner is not required to use another effective birth control method; b. Male subj
Exclusion Criteria
- •A subject will not be eligible to participate in the study if they meet any of the following criteria: 1. The subject has an anticipated need for hospitalization within 24 hours of signing the Study ICF. Note: Emergency room or hospital observation status for an anticipated duration of less than <24 hours is not considered as hospitalization., 5. The subject has COPD GOLD Class IV [Venkatesan P., 2022];, 6. The subject has a malignant tumor or history of malignancy that may interfere with the aims of the study or a subject completing the study., 7. The subject has prior receipt of or is waiting to receive a bone marrow, stem cell, or solid organ transplantation., 8. The subject has a known positive human immunodeficiency virus infection, active hepatitis A virus infection, chronic hepatitis B virus infection, and/or current hepatitis C virus (HCV) infection; subjects with a history of HCV infection who have achieved a documented sustained virologic response 12 weeks after completion of HCV therapy may be enrolled., 9. The subject has a history of chronic liver disease (e.g., hemochromatosis, Wilson’s disease, cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, and/or alcoholic liver disease); a history of active biliary disease (e.g., primary sclerosing cholangitis); or a history of portal hypertension. A diagnosis of hepatic steatosis (fatty liver) is not exclusionary., 15. Known hypersensitivity to the investigational product or any of its excipients., 16. Receiving dialysis or have known severe renal impairment (ie., eGFR <30 mL/min/ 1.73 m2 within 6 months of the screening visit, using the serum creatinine-based CKD-EPI formula)., 10. The subject has any of the following cardiac conditions: any congenital heart disease, congenital long QT syndrome, or any clinical manifestation resulting in QT interval prolongation., 11. The subject has use of or intention to use excluded or contraindicated medication(s) or supplements, including any medication known to be a moderate or strong inducer or inhibitor of the cytochrome P450 3A4 enzyme (see Section 5.8) within 14 days prior to signing the Study ICF., 12. The subject has received an RSV vaccine within 12 months prior to signing the Study ICF., 13. The subject has received any investigational agent within 30 days (or 5 half-lives of that investigational agent, whichever is longer) prior to the first dose of study drug;, 14. The subject has a history of or is currently experiencing a medical condition or any other finding (including laboratory test results) that, in the opinion of the Investigator, might confound the results of the study; pose an additional risk in administering study drug to the subject; could prevent, limit, or confound the protocol specified assessments; or deems the subject unsuitable for the study., 2. The subject has concomitant respiratory infections that are viral (other than RSV but including influenza), bacterial, or fungal, including systemic bacterial or fungal infections, within 7 days prior to signing the Study ICF., 3. The subject has a SARS-CoV-2 test result that is positive within 28 days prior to signing the Study ICF., 4. The subject is pregnant or nursing.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Phase IIB Psoriatic Arthritis Dose Ranging Study for BMS-945429 insubjects who are not responding to NSAIDs or non-biologic DMARDtherapyArthritis, PsoriaticMedDRA version: 14.1Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-004016-29-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO224
Active, not recruiting
Not Applicable
Phase IIB Psoriatic Arthritis Dose Ranging Study for BMS-945429 in subjects who are not responding to NSAIDs or non-biologic DMARD therapyEUCTR2011-004016-29-DEBristol-Myers Squibb International Corporation224
Active, not recruiting
Phase 1
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BG9924 When Given in Combination With Methotrexate to Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF TherapyRheumatoid ArthritisEUCTR2006-005467-26-GBBiogen Idec Ltd
Active, not recruiting
Phase 1
A study to learn how well the drug EDP 938-102 works and how safe it is in people who have had a bone marrow transplant and are infected with Respiratory Syncytial VirusRespiratory syncytial virus (RSV)MedDRA version: 21.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002213-18-FREnanta Pharmaceuticals, Inc.200
Completed
Phase 2
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of PRV-015 in Adult Patients with Non-Responsive Celiac Disease as an Adjunct to a Gluten-free Diet10027424celiac diseaseNL-OMON52134Provention Bio, Inc.5